[ad_1]
Researchers from the Rostock University Medical Center and the Viennese biotechnology company Themis have succeeded in developing a vaccine against the dangerous chikungunya virus. As there is no specific treatment for chikungunya, vaccination is of particular importance, said Unimedizin Rostock, head of the Department of Tropical Medicine and Infectiology, Emil Reisinger, in a study published Tuesday in the newspaper "The Lancet ", chikungunya fever is a viral infection transmitted by Aedes mosquitoes, widespread in recent years. It occurs mainly in tropical and subtropical regions. "In the treatment groups, after two injections, antibodies were detected in 86.4 to 100% of the vaccinated persons." The vaccine is based on a measles virus.
Editor 's Note: This message from the German News Agency (dpa) is part of an automated offering posted on our website. Neither the content nor the spelling has been checked by the t-online.de editorial staff. The dpa works but strictly according to journalistic standards. If you still notice errors, we look forward to hearing from you. thank you so much
Source link
